Skip to main content

Table 4 Predictors of LUNDEX-corrected HAQ response. Odds ratios (95% confidence intervals)

From: Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

 6 months12 months
UnivariateMultivariateUnivariateMultivariate
Male sex1.07 (0.73–1.58)*1.32 (0.91–1.90)**
≥ 2 bDMARDsReference (1.0)Reference (1.0)Reference (1.0)Reference (1.0)
Bionaïve2.25 (1.50–3.38)2.31 (1.49–3.60)2.05 (1.37–3.07)2.05 (1.37–3.07)
1 bDMARD1.02 (0.71–1.47)*0.70 (0.48–1.04)**
DAS28-CRP (per SD) at baseline1.48 (1.26–1.74)*1.38 (1.17–1.62)**
DAS28 (per unit) at baseline1.40 (1.23–1.60)*1.27 (1.12–1.45)**
VAS pain (per SD) at baseline1.45 (1.23–1.70)*1.24 (1.05–1.47)**
Methotrexate at baseline1.50 (1.10–2.05)*1.39 (1.01–1.90)**
HAQ score (per SD) at baseline1.52 (1.29–1.78)1.73 (1.46–2.05)1.24 (1.06–1.45)**
Disease duration (per SD) at baseline0.77 (0.65–0.91)0.74 (0.61–0.89)0.78 (0.65–0.92)**
Age (per SD) at baseline0.93 (0.80–1.08)*1.00 (0.86–1.17)**
Glucocorticoids at baseline0.75 (0.55–1.01)*0.83 (0.61–1.13)**
csDMARDs at baseline1.30 (0.94–1.81)*1.17 (0.84–1.62)**
s.c. abatacept administrationReference (1.0)*Reference (1.0)*
i.v. abatacept administration0.98 (0.73–1.33)*0.97 (0.71–1.32)**
  1. *Not included in the final model. The first multivariate model in the stepwise analysis included bDMARD exposure, DAS28-CRP, DAS28, VAS pain, methotrexate at baseline, HAQ-DI, disease duration, glucocorticoids at baseline, and csDMARDs at baseline. **Not included in the final model. The first multivariate model in the stepwise analysis included sex, bDMARD exposure, DAS28-CRP, DAS28, VAS pain, methotrexate at baseline, HAQ-DI, and disease duration. Multivariate model includes 862 patients at 6 months and 943 at 12 months